Jazz Pharmaceuticals plc
JAZZ
Market Cap$6.91B
Close$
$126.07
19.9% upside
Current Fair Value
19.9% upsideUndervalued by 19.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.91 Billion |
|---|---|
| Enterprise Value | $11.31 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $4.78 |
| Beta | 0.5 |
| Outstanding Shares | 63,062,356 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 20.88 |
|---|---|
| PEG | 34.01 |
| Price to Sales | 1.7 |
| Price to Book Ratio | 1.78 |
| Enterprise Value to Revenue | 2.89 |
| Enterprise Value to EBIT | 17.39 |
| Enterprise Value to Net Income | 28 |
| Total Debt to Enterprise | 0.51 |
| Debt to Equity | 1.53 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Jazz Pharmaceuticals plc
1,210 employeesJazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of...